Tags

Type your tag names separated by a space and hit enter

Review of the clinical effectiveness of the neuraminidase inhibitors against influenza B viruses.
Expert Rev Anti Infect Ther. 2013 Nov; 11(11):1135-45.ER

Abstract

Influenza A and B viruses cause significant morbidity and mortality worldwide each year. The neuraminidase inhibitors (NAIs) are the most commonly used class of influenza antiviral drugs for the treatment of infected patients. In vitro studies have shown that influenza B viruses are significantly less susceptible to oseltamivir and other neuraminidase inhibitors compared with influenza A viruses. Following analysis of published clinical studies, we show that oseltamivir does appear to have lower effectiveness in patients infected with influenza B virus compared with influenza A infected patients, but due to insufficient studies on zanamivir, laninamivir or peramivir, it was not possible to conclude the relative effectiveness of these drugs against influenza A virus compared with B virus.

Authors+Show Affiliations

WHO Collaborating Centre for Reference and Research on Influenza, North Melbourne, Victoria, Australia.No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

24093683

Citation

Farrukee, Rubaiyea, et al. "Review of the Clinical Effectiveness of the Neuraminidase Inhibitors Against Influenza B Viruses." Expert Review of Anti-infective Therapy, vol. 11, no. 11, 2013, pp. 1135-45.
Farrukee R, Mosse J, Hurt AC. Review of the clinical effectiveness of the neuraminidase inhibitors against influenza B viruses. Expert Rev Anti Infect Ther. 2013;11(11):1135-45.
Farrukee, R., Mosse, J., & Hurt, A. C. (2013). Review of the clinical effectiveness of the neuraminidase inhibitors against influenza B viruses. Expert Review of Anti-infective Therapy, 11(11), 1135-45. https://doi.org/10.1586/14787210.2013.842466
Farrukee R, Mosse J, Hurt AC. Review of the Clinical Effectiveness of the Neuraminidase Inhibitors Against Influenza B Viruses. Expert Rev Anti Infect Ther. 2013;11(11):1135-45. PubMed PMID: 24093683.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Review of the clinical effectiveness of the neuraminidase inhibitors against influenza B viruses. AU - Farrukee,Rubaiyea, AU - Mosse,Jennifer, AU - Hurt,Aeron C, Y1 - 2013/10/07/ PY - 2013/10/8/entrez PY - 2013/10/8/pubmed PY - 2014/6/10/medline SP - 1135 EP - 45 JF - Expert review of anti-infective therapy JO - Expert Rev Anti Infect Ther VL - 11 IS - 11 N2 - Influenza A and B viruses cause significant morbidity and mortality worldwide each year. The neuraminidase inhibitors (NAIs) are the most commonly used class of influenza antiviral drugs for the treatment of infected patients. In vitro studies have shown that influenza B viruses are significantly less susceptible to oseltamivir and other neuraminidase inhibitors compared with influenza A viruses. Following analysis of published clinical studies, we show that oseltamivir does appear to have lower effectiveness in patients infected with influenza B virus compared with influenza A infected patients, but due to insufficient studies on zanamivir, laninamivir or peramivir, it was not possible to conclude the relative effectiveness of these drugs against influenza A virus compared with B virus. SN - 1744-8336 UR - https://www.unboundmedicine.com/medline/citation/24093683/Review_of_the_clinical_effectiveness_of_the_neuraminidase_inhibitors_against_influenza_B_viruses_ L2 - http://www.tandfonline.com/doi/full/10.1586/14787210.2013.842466 DB - PRIME DP - Unbound Medicine ER -